DNA/RNA Synthesis Inhibitor

Distamycin A hydrochloride (NSC-82150 hydrochloride) is an oligopeptide pyrrole antibiotic. Distamycin A hydrochloride inhibits DNA-dependent DNA polymerase and inhibits DNA-dependent RNA polymerase by blocking sigma-dependent initiation complex formation. Distamycin A hydrochloride exhibits antiviral activity against DNA viruses, antibacterial activity against Gram-positive bacteria and fungi, and antiproliferative activity against leukemia cells. Distamycin A hydrochloride can be used in research on viral infections, leukemia, and cancer.

2'-(2-Nitrobenzyl)-ATP is an rATP analog. 2'-(2-Nitrobenzyl)-ATP acts as a transcription terminator, inhibiting further RNA chain elongation by T7 RNA polymerase.

Rifaximin (Standard) is the analytical standard of Rifaximin. This product is intended for research and analytical applications. Rifaximin, a gastrointestinal-selective antibiotic, binds the β-subunit of bacterial DNA-dependent RNA polymerase, resulting in inhibition of bacterial RNA synthesis. Rifaximin susceptibility is higher against Gram-positive strains (MIC: 0.03-5 mg/ml) compared to Gram-negative bacteria (MIC: 8-50 mg/mL).

Dithranol (Standard) is the analytical standard of Dithranol. This product is intended for research and analytical applications. Dithranol (Anthralin) is an anthraquinone derivative, with potent anti-psoriatic effects. Dithranol can inhibit DNA replication and repair.

CNDAC is a metabolite of the orally active agent Sapacitabine (HY-16445), and a nucleoside analog. CNDAC induces DNA damage and apoptosis.

PolQi2 (Standard) is the analytical standard of PolQi2 (HY-150279). This product is intended for research and analytical applications. PolQi2 is a PolΘ inhibitor that targets and inhibits alt-EJ (alternative end-joining) repair by inhibiting the helicase domain at the N-terminus of PolΘ. PolQi2 enhances the precision and integration efficiency of gene editing at different loci and in various cell lines. Furthermore, the combined use of PolQi2 with DNA-PK inhibitors reduces the off-target effects of Cas9. PolQi2 can be used in gene editing research.

Fluchloralin is a dinitroaniline herbicide that effectively controls annual gramineous and broadleaf weeds primarily by inhibiting tubulin synthesis and cell division. Fluchloralin exhibits cytotoxicity and genotoxicity, and promotes cell apoptosis by activating apoptotic signaling proteins, forming DNA ladder bands, inducing cell shrinkage and nuclear fragmentation.

Lincomycin (U-10149) hydrochloride monohydrate (Standard) is the analytical standard of Lincomycin hydrochloride monohydrate (HY-B1358). This product is intended for research and analytical applications. Lincomycin hydrochloride monohydrate is an orally active lincosamide antibiotic. Lincomycin hydrochloride monohydrate binds to the ribosomes of Gram-positive bacteria to inhibit protein synthesis. Lincomycin hydrochloride monohydrate can inhibit chloroplast translation, disrupt chloroplast integrity, and activate chloroplast-to-nucleus retrograde signaling in Arabidopsis thaliana seedlings. Lincomycin hydrochloride monohydrate induces alterations in lipid profiles and liver injury, disrupts blood glucose and insulin levels, and increases growth rate in mice.

Pazufloxacin is an orally active fluoroquinolone antimicrobial agent. Pazufloxacin inhibits DNA gyrase with IC₅₀ values of 0.88 μg/mL (E. coli) and 1.9 μg/mL (P. aeruginosa). Pazufloxacin exhibits broad-spectrum antimicrobial activity, with MIC₉₀ values ranging from 0.025 to 100 μg/mL against Gram-positive and Gram-negative bacteria, non-fermenting bacteria, Legionella spp., and anaerobic bacteria. Pazufloxacin is indicated for research on systemic infections, lung infections, urinary tract infections, and Legionella pneumonia.

DS21412020 is a fluoroquinolone antibacterial agent. DS21412020 inhibits bacterial DNA gyrase (GyrA) and topoisomerase IV, leading to DNA breaks. DS21412020 exhibits significant activity against Gram-positive bacteria such as Staphylococcus aureus (MIC = 0.006 μg/mL), Streptococcus pneumoniae (MIC = 0.05 μg/mL), and Methicillin (HY-121544)-resistant Staphylococcus aureus (MIC = 0.2 μg/mL), and Gram-negative bacteria such as Escherichia coli (MIC = 0.006 μg/mL) and Pseudomonas aeruginosa (MIC = 0.78 μg/mL). DS21412020 significantly reduces bacterial load in mouse pneumonia and MRSA infection models. DS21412020 can be used in the development of next-generation quinolone antibiotics.

Dimethyl biphenyl-4,4'-dicarboxylate (Standard) is the analytical standard of Dimethyl biphenyl-4,4'-dicarboxylate (HY-128854). This product is intended for research and analytical applications. Dimethyl biphenyl-4,4'-dicarboxylate (Biphenyl dimethyl dicarboxylate) is a hepatoprotective agent. Dimethyl biphenyl-4,4'-dicarboxylate stimulates the Jak/Stat signaling pathway and induces the expression of IFN-α-stimulated genes, particularly 6-16 and ISG12. Dimethyl biphenyl-4,4'-dicarboxylate inhibits the replication of pregenomic RNA and HBeAg. Polymer micelles loaded with Dimethyl biphenyl-4,4'-dicarboxylate can serve as carriers for the compound. Dimethyl biphenyl-4,4'-dicarboxylate can be used as an auxiliary improving agent for chronic hepatitis. Dimethyl biphenyl-4,4'-dicarboxylate is applicable to research related to chronic hepatitis B.

PMEG is a nuclear DNA polymerases α, δ, and ε inhibitor that causes DNA chain termination, inhibits DNA synthesis, induces cytotoxicity in dividing cells. PMEG is an acyclic nucleotide phosphonate that forms an active phosphorylated metabolite, PMEG diphosphate, within cells. PMEG has activity against leukemia and melanoma in rodent models. PMEG has poor cell permeability; its prodrug is Rabacfosadine (GS-9219) (HY-13640). PMEG shows antiviral activity against against various DNA virus infections including murine cytomegalovirus (MCMV) and human cytomegalovirus (HCMV). PMEG can be used for the research of non-hodgkin's lymphoma^[1][2].

Rabdosin B is an ent-kaurene diterpenoid with anticancer effects. Rabdosin B induces DNA damage in cells, and inhibits lettuce root hair development of seedlings.

Tetrahydrouridine (Standard) is the analytical standard of Tetrahydrouridine. This product is intended for research and analytical applications. Tetrahydrouridine dihydrate is potent inhibitor of cytidine deaminase (CDA), which competitively blocks the enzyme's active site more effectively than intrinsic cytidine.

Asulacrine isethionate (CI-921 isethionate) is a derivative of Amsacrine (HY-13551), a Topoisomerase II inhibitor and an anticancer agent. Asulacrine isethionate binds to DNA via intercalation, forming stable complexes with long residence times at DNA sites. Asulacrine isethionate mediates DNA breakage and DNA-protein cross-linking. Asulacrine isethionate exhibits anticancer activity against leukemia or lung cancer. Asulacrine isethionate can be used in research related to breast cancer, lung cancer, mouse solid tumors and leukemia.

3-Deazauridine (Standard) is the analytical standard of 3-Deazauridine (HY-105336). This product is intended for research and analytical applications. 3-Deazauridine (NSC 126849) is a uridine analogue. 3-Deazauridine competitively inhibits cytidine triphosphate synthase to inhibit the biosynthesis of cytidine-5'-triphosphate. 3-Deazauridine acts synergistically with several antineoplastic agents, acting as a biological response modifier.

Endusamycin can inhibit the protein and nucleic acid synthesis of Ehrlician ascites cancer cells, and has no anti-bacterial and anti-yeast effect.

TP-061 (Compound 30) is a Brr2 inhibitor with an IC₅₀ of 42 nM for Brr2 ATPase.

Clofazimine (Standard) is the analytical standard of Clofazimine. This product is intended for research and analytical applications. Clofazimine is an orally-active anti-mycobacterial agent with a wide range of anti-mycobacterial activity including leprosy and tuberculosis. Clofazimine exerts anti-inflammatory activities and anti-tumor activities by interfering DNA replication and inhibiting IL2 (IC₅₀ = 1.10 ± 0.26 μM, Jurkat T) production. Clofazimine can be used in mycobacterial and cancer research.